Wang Xinyuan, Kan Yutian, Chen Leiyuan, Ge Peng, Ding Tingting, Zhai Qiongli, Yu Yong, Wang Xiaofang, Zhao Zhigang, Yang Hongliang, Liu Xianming, Li Lanfang, Qiu Lihua, Qian Zhengzi, Zhang Huilai, Wang Yafei, Zhao Haifeng
Department of Hematology and Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, P.R. China.
Department of Laboratory, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, P.R. China.
Oncol Lett. 2020 May;19(5):3487-3494. doi: 10.3892/ol.2020.11452. Epub 2020 Mar 10.
A number of studies suggest an association between miRNAs and diffuse large B-cell lymphoma (DLBCL). The present study aimed to investigate the prognostic value of microRNA (miR-150) in primary gastrointestinal (PGI)-DLBCL, by assessing the association between miR-150 expression and clinicopathological characteristics in patients with PGI-DLBCL. A total of 84 patients diagnosed with PGI-DLBCL were recruited and both tumor and adjacent non-tumor tissue samples were collected. miR-150 expression was assessed via reverse transcription-quantitative (RT-q)PCR analysis. The results demonstrated that miR-150 expression was significantly lower in PGI-DLBCL tissues compared with adjacent non-tumor tissues. Furthermore, receiver operating characteristic (ROC) curve analysis indicated that the optimal cut-off value of miR-150 for predicting survival was 8.965 with high sensitivity (79.8%) and specificity (77.1%). Patients were divided into two groups according to this cut-off value, as follows: High (n=18) and low expression (n=66) groups. Low miR-150 expression was significantly associated with clinical stage, International Prognostic Index (IPI), Eastern Cooperative Oncology Group status and use of rituximab. RT-qPCR analysis demonstrated that miR-150 expression was significantly lower in patients with high IPI scores compared with patients with low IPI scores. Downregulated miR-150 expression was significantly associated with shorter overall survival (OS) time and progression-free survival (PFS) time in patients with PGI-DLBCL. Furthermore, miR-150 level and IPI score were identified as two risk factors for OS and PFS. The diagnostic value of miR-150 was evaluated via ROC curve analysis, with an area under the curve value of 0.882. Taken together, the results of the present study suggest that miR-150 is a potential diagnostic marker of PGI-DLBCL, and may also serve as a useful prognostic factor for survival outcomes in patients with PGI-DLBCL.
多项研究表明，微小RNA（miRNA）与弥漫性大B细胞淋巴瘤（DLBCL）之间存在关联。本研究旨在通过评估原发性胃肠道（PGI）-DLBCL患者中miR-150表达与临床病理特征之间的关联，来探讨微小RNA（miR-150）在PGI-DLBCL中的预后价值。共招募了84例诊断为PGI-DLBCL的患者，并采集了肿瘤组织和相邻的非肿瘤组织样本。通过逆转录定量（RT-q）PCR分析评估miR-150的表达。结果表明，与相邻的非肿瘤组织相比，PGI-DLBCL组织中miR-150的表达显著降低。此外，受试者工作特征（ROC）曲线分析表明，用于预测生存的miR-150的最佳临界值为8.965，具有高敏感性（79.8%）和特异性（77.1%）。根据该临界值将患者分为两组，如下：高表达组（n = 18）和低表达组（n = 66）。miR-150低表达与临床分期、国际预后指数（IPI）、东部肿瘤协作组状态以及利妥昔单抗的使用显著相关。RT-qPCR分析表明，IPI评分高的患者中miR-150的表达显著低于IPI评分低的患者。PGI-DLBCL患者中miR-150表达下调与总生存期（OS）时间和无进展生存期（PFS）时间缩短显著相关。此外，miR-150水平和IPI评分被确定为OS和PFS的两个危险因素。通过ROC曲线分析评估miR-150的诊断价值，曲线下面积值为0.882。综上所述，本研究结果表明，miR-150是PGI-DLBCL的潜在诊断标志物，也可能是PGI-DLBCL患者生存结局的有用预后因素。
